Less may be more: smaller lung surgery tested after powerful Pre-Treatment
NCT ID NCT07612722
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether removing only part of a lung lobe (sub-lobectomy) is as good as removing the whole lobe (lobectomy) in people with stage IIA-IIIB non-small cell lung cancer who have already received chemotherapy plus immunotherapy. About 585 participants will be randomly assigned to one surgery or the other. The main goal is to see if the smaller surgery offers similar cancer control while better preserving lung function and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- surgery (sub-lobectomy or lobectomy)
- What this could lead to
- If successful, this could show that a smaller lung surgery (sub-lobectomy) is as effective as removing the whole lobe, while preserving more lung function and improving quality of life.
- What could go wrong
- This is a non-inferiority trial, meaning it aims to prove the smaller surgery is not worse—not necessarily better. Results may not apply to all lung cancer patients, and there are standard surgical risks like infection or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong provincial people's hospital
RECRUITINGGuangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?
- Can zapping tumors before surgery boost lung cancer treatment?
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?